Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : to test experimental HIV vaccine in U.S., Europe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2019 | 11:17am EDT
FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the NYSE in New York

(Reuters) - Johnson & Johnson said on Friday it plans to conduct a late-stage study of its investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.

The drugmaker already has a mid-stage HIV vaccine study underway in five southern African countries.

There are currently no vaccines for HIV, a virus that weakens the body's immune system.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
10:51pJOHNSON & JOHNSON INVESTIGATION UPDA : Kahn Swick & Foti, LLC Continues to Inves..
BU
07:31aJOHNSON & JOHNSON : J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in M..
DJ
07/18JOHNSON & JOHNSON : Oklahoma County seeking lawsuit against opioid manufacturers
AQ
07/18JOHNSON & JOHNSON : DRC rejects clinical trial for experimental Ebola vaccine
AQ
07/17JOHNSON & JOHNSON : Extends Long-Standing Donation Program to Support Global Eff..
AQ
07/17GENMAB : Announces Net Sales of DARZALEX for Second Quarter of 2019
AQ
07/17JOHNSON & JOHNSON : 's Baltic net profits down 42% to EUR 1.2 million
AQ
07/17J&J Lifts Forecast As Suits Weigh On Its Shares -- WSJ
DJ
07/17JOHNSON & JOHNSON : Pharma strength boosts Johnson & Johnson profit
AQ
07/16Wall Street slips as bank earnings, Trump trade comments weigh
RE
More news
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 6 116 M
Yield 2019 2,87%
P/E ratio 2019 19,4x
P/E ratio 2020 17,2x
EV / Sales2019 4,32x
EV / Sales2020 4,05x
Capitalization 346 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 149,00  $
Last Close Price 130,31  $
Spread / Highest target 29,7%
Spread / Average Target 14,3%
Spread / Lowest Target -4,84%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.34%350 653
PFIZER-2.08%239 061
ROCHE HOLDING LTD.11.42%234 924
ROCHE HOLDING13.37%234 924
NOVARTIS24.46%217 699
MERCK AND COMPANY8.22%212 897